Is there a new dawn for selective mineralocorticoid receptor antagonism?

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 5, 2014, Pages 456-461

  Luther, James M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

aldosterone; hyperkalemia; mineralocorticoid receptor

Indexed keywords

BENZENESULFONAMIDE DERIVATIVE; DIHYDROPYRIDINE DERIVATIVE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PYRAZOLINE DERIVATIVE; ANTIHYPERTENSIVE AGENT;

DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; HYPERKALEMIA; HYPERTENSION; INCIDENCE; KIDNEY DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ANIMAL; BLOOD PRESSURE; BLOOD VESSEL; CHEMICALLY INDUCED; DRUG DESIGN; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD VESSELS; DRUG DESIGN; HUMANS; HYPERKALEMIA; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84906101087     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000051     Document Type: Review

References (41)

1. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
2. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999; 341:709-717.
3. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925-930.
4. Ouzan J, Perault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15:333-339.
5. Eschalier R, McMurray JJ, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: Analyses of the EMPHASIS-HF study subgroups (eplerenone in mild patients hospitalization and survival study in heart failure). J Am Coll Cardiol 2013; 62:1585-1593.
6. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. Mol Cell Endocrinol 2012; 350:310-317.
7. Funder JW. Mineralocorticoid-receptor blockade, hypertension and heart failure. Nat Clin Pract Endocrinol Metab 2005; 1:4-5.
8. Pruthi D, McCurley A, Aronovitz M, et al. Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol 2014; 34:355-364.
9. Galmiche G, Pizard A, Gueret A, et al. Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension 2014; 63:520-526.
10. McCurley A, Pires PW, Bender SB, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 2012; 18:1429-1433.
11. Dupont JJ, Hill MA, Bender SB, et al. Aldosterone and vascular mineralocorticoid receptors: Regulators of ion channels beyond the kidney. Hypertension 2014; 63:632-637.
12. Fraccarollo D, Berger S, Galuppo P, et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 2011; 123:400-408.
13. Casimiro-Garcia A, Piotrowski DW, Ambler C, et al. Identification of (r)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1h-pyrazol-3-yl) -2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist. J Med Chem 2014; 57:4273-4288.
14. Souque A, Fagart J, Couette B, et al. The mineralocorticoid activity of progesterone derivatives depends on the nature of the c18 substituent. Endocrinology 1995; 136:5651-5658.
15. Meyers MJ, Arhancet GB, Hockerman SL, et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-Tetrahydro-2H- benzo[g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem 2010; 53:5979-6002.
16. Barfacker L, Kuhl A, Hillisch A, et al. Discovery of bay 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012; 7:1385-1403.
17. Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010; 285:29932-29940.
18. Cox JM, Chu HD, Yang C, et al. Mineralocorticoid receptor antagonists: Identification of heterocyclic amide replacements in the oxazolidinedione series. Bioorg Med Chem Lett 2014; 24:1681-1684.
19. Nariai T, Fujita K, Mori M, et al. Sm-368229, a novel selective and potent nonsteroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity. J Pharmacol Sci 2011; 115:346-353.
20. de Gasparo M, Whitebread SE, Preiswerk G, et al. Antialdosterones: Incidence and prevention of sexual side effects. J Steroid Biochem 1989; 32:223-227.
21. Fagart J, Seguin C, Pinon GM, et al. The met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor. Mol Pharmacol 2005; 67:1714-1722.
22. Menard J. The 45-year story of the development of an antialdosterone more specific than spironolactone. Mol Cell Endocrinol 2004; 217:45-52.
23. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364:11-21.
24. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370:1383-1392.
25. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351:543-551.
26. Witham MD, Gillespie ND, Struthers AD. Tolerability of spironolactone in patients with chronic heart failure-A cautionary message. Br J Clin Pharmacol 2004; 58:554-557.
27. Rossignol P, Cleland JG, Bhandari S, et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: Insights from the eplerenone postacute myocardial infarction heart failure efficacy and survival study. Circulation 2012; 125:271-279.
28. Neel DA, Brown ML, Lander PA, et al. 3,3-bisaryloxindoles as mineralocorticoid receptor antagonists. Bioorg Med Chem Lett 2005; 15:2553-2557.
29. Bell MG, Gernert DL, Grese TA, et al. (S)-N-{3-[1-cyclopropyl-1-(2,4- difluorophenyl)-ethyl]-1H-indol-7-yl}-methanesulf onamide: A potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor. J Med Chem 2007; 50:6443-6445.
30. Dietz JD, Du S, Bolten CW, et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51:742-748.
31. Arhancet GB, Woodard SS, Iyanar K, et al. Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists. J Med Chem 2010; 53:5970-5978.
32. Schupp N, Kolkhof P, Queisser N, et al. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J 2011; 25:968-978.
33. Lavall D, Selzer C, Schuster P, et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem 2014; 289:6656-6668.
34. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel nonsteroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur Heart J 2013; 34:2453-2463.
35. Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of ARTS: A randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail 2012; 14:668-675.
36. Nariai T, Fujita K, Mori M, et al. SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats. J Cardiovasc Pharmacol 2012; 59:458-464.
37. Nariai T, Fujita K, Mori M, et al. Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-Treated rats. Pharmacology 2012; 89:44-52.
38. Alexander EA, Levinsky NG. An extrarenal mechanism of potassium adaptation. J Clin Invest 1968; 47:740-748.
39. Adler S. An extrarenal action of aldosterone on mammalian skeletal muscle. Am J Physiol 1970; 218:616-621.
40. Goldfarb S, Cox M, Singer I, et al. Acute hyperkalemia induced by hyperglycemia: Hormonal mechanisms. Ann Intern Med 1976; 84:426-432.
41. Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20:2641-2650.